PPAR γ agonists in adaptive immunity: What do immune disorders and their models have to tell us?

32Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Adaptive immunity has evolved as a very powerful and highly specialized tool of host defense. Its classical protagonists are lymphocytes of the T- and B-cell lineage. Cytokines and chemokines play a key role as effector mechanisms of the adaptive immunity. Some autoimmune and inflammatory diseases are caused by disturbance of the adaptive immune system. Recent advances in understanding the pathogenesis of autoimmune diseases have led to research on new molecular and therapeutic targets. PPARγ are members of the nuclear receptor superfamily and are transcription factors involved in lipid metabolism as well as innate and adaptive immunity. PPARγ is activated by synthetic and endogenous ligands. Previous studies have shown that PPAR agonists regulate T-cell survival, activation and T helper cell differentiation into effector subsets: Th1, Th2, Th17, and Tregs. PPARγ has also been associated with B cells. The present review addresses these issues by placing PPARγ agonists in the context of adaptive immune responses and the relation of the activation of these receptors with the expression of cytokines involved in adaptive immunity. © 2013 Laurindo Ferreira da Rocha Junior et al.

Cite

CITATION STYLE

APA

Da Rocha Junior, L. F., Dantas, A. T., Duarte, Â. L. B. P., De Melo Rego, M. J. B., Pitta, I. D. R., & Pitta, M. G. D. R. (2013). PPAR γ agonists in adaptive immunity: What do immune disorders and their models have to tell us? PPAR Research. https://doi.org/10.1155/2013/519724

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free